Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.
Morgan NH, Stanford IM, Woodhall GL (September 2009). „Functional CB2 type cannabinoid receptors at CNS synapses”. Neuropharmacology57 (4): 356–68. DOI:10.1016/j.neuropharm.2009.07.017. PMID19616018.
Ishiguro H, Horiuchi Y, Ishikawa M, Koga M, Imai K, Suzuki Y, Morikawa M, Inada T, Watanabe Y, Takahashi M, Someya T, Ujike H, Iwata N, Ozaki N, Onaivi ES, Kunugi H, Sasaki T, Itokawa M, Arai M, Niizato K, Iritani S, Naka I, Ohashi J, Kakita A, Takahashi H, Nawa H, Arinami T (May 2010). „Brain cannabinoid CB2 receptor in schizophrenia”. Biological Psychiatry67 (10): 974–82. DOI:10.1016/j.biopsych.2009.09.024. PMID19931854.
Eissenstat, M. A.; Bell, M. R.; D'ambra, T. E.; Alexander, E. J.; Daum, S. J.; Ackerman, J. H.; Gruett, M. D.; Kumar, V. i dr.. (1995). „Aminoalkylindoles: Structure-Activity Relationships of Novel Cannabinoid Mimetics”. Journal of Medicinal Chemistry38 (16): 3094. DOI:10.1021/jm00016a013. PMID7636873.
Frost, J. M.; Dart, M. J.; Tietje, K. R.; Garrison, T. R.; Grayson, G. K.; Daza, A. V.; El-Kouhen, O. F.; Miller, L. N. i dr.. (2008). „Indol-3-yl-tetramethylcyclopropyl Ketones: Effects of Indole Ring Substitution on CB2 Cannabinoid Receptor Activity”. Journal of Medicinal Chemistry51 (6): 1904. DOI:10.1021/jm7011613. PMID18311894.
Adam, J. M.; Cairns, J.; Caulfield, W.; Cowley, P.; Cumming, I.; Easson, M.; Edwards, D.; Ferguson, M. i dr.. (2010). „Design, synthesis, and structure–activity relationships of indole-3-carboxamides as novel water soluble cannabinoid CB1 receptor agonists”. MedChemComm1: 54. DOI:10.1039/c0md00022a.
Morgan NH, Stanford IM, Woodhall GL (September 2009). „Functional CB2 type cannabinoid receptors at CNS synapses”. Neuropharmacology57 (4): 356–68. DOI:10.1016/j.neuropharm.2009.07.017. PMID19616018.
Ishiguro H, Horiuchi Y, Ishikawa M, Koga M, Imai K, Suzuki Y, Morikawa M, Inada T, Watanabe Y, Takahashi M, Someya T, Ujike H, Iwata N, Ozaki N, Onaivi ES, Kunugi H, Sasaki T, Itokawa M, Arai M, Niizato K, Iritani S, Naka I, Ohashi J, Kakita A, Takahashi H, Nawa H, Arinami T (May 2010). „Brain cannabinoid CB2 receptor in schizophrenia”. Biological Psychiatry67 (10): 974–82. DOI:10.1016/j.biopsych.2009.09.024. PMID19931854.
Eissenstat, M. A.; Bell, M. R.; D'ambra, T. E.; Alexander, E. J.; Daum, S. J.; Ackerman, J. H.; Gruett, M. D.; Kumar, V. i dr.. (1995). „Aminoalkylindoles: Structure-Activity Relationships of Novel Cannabinoid Mimetics”. Journal of Medicinal Chemistry38 (16): 3094. DOI:10.1021/jm00016a013. PMID7636873.
Frost, J. M.; Dart, M. J.; Tietje, K. R.; Garrison, T. R.; Grayson, G. K.; Daza, A. V.; El-Kouhen, O. F.; Miller, L. N. i dr.. (2008). „Indol-3-yl-tetramethylcyclopropyl Ketones: Effects of Indole Ring Substitution on CB2 Cannabinoid Receptor Activity”. Journal of Medicinal Chemistry51 (6): 1904. DOI:10.1021/jm7011613. PMID18311894.